Compare SVRE & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SVRE | CMND |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.6M |
| IPO Year | 2021 | 2021 |
| Metric | SVRE | CMND |
|---|---|---|
| Price | $1.25 | $5.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 45.8K | 32.7K |
| Earning Date | 08-14-2026 | 09-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,756.92 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.07 |
| 52 Week High | $6.30 | $7.16 |
| Indicator | SVRE | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 73.11 |
| Support Level | $1.01 | $0.58 |
| Resistance Level | $1.96 | $7.16 |
| Average True Range (ATR) | 0.21 | 0.46 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 32.11 | 27.07 |
Saverone 2014 Ltd is engaged in the design, development, and commercialization of transportation and safety solutions, designed to prevent car accidents based on its patented technology of detecting, analyzing, and locating cellular phone radio frequency, or RF signals. The company is developing two product lines: the first is an In-Cabin Driver Distraction Prevention Solution (known as SaverOne system), or DDPS; and the second is an Advanced Driver-Assistance System, or ADAS, product that detects vulnerable road users, or VRUs, and provides a warning to the vehicle regarding potential collision. Geographically, Saverone generates maximum revenue from Europe and the rest from Israel.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.